Literature DB >> 16375825

Verruculogen production in airborne and clinical isolates of Aspergillus fumigatus Fres.

Ivan Kosalec1, Maja Segvić Klarić, Stjepan Pepeljnjak.   

Abstract

Among airborne aspergilli sampled in outdoor air of the Zagreb area (2002/2003), Aspergillus niger (v. Teigh.) and A. fumigatus (Fres.) were the most abundant species (20-30%), with low mean annual concentrations (0.21-1.04 CFU m-3). Higher concentrations of A. fumigatus were observed in autumn and winter (0.5-1.05 CFU m-3) than in spring and summer (0-0.4 CFU m-3). On the other hand, A. fumigatus was found to be the most frequent isolate from upper and/or lower respiratory tracts of imunocompromised patients in many studies. This species produces several mycotoxins, including the tremorgenic mycotoxin verruculogen that can be found in spores and during myceliar growth. Verruculogen production ability was tested on 30 airborne and 33 clinical isolates of A. fumigatus. In both groups, high percentage of verruculogen-producing strains was noticed (84% of airborne and 91% of clinical isolates). Verruculogen production was not significantly different in the groups of airborne isolates (0.34+/-0.16 mg mL-1), and clinical isolates (0.26+/-0.19 mg mL-1).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16375825

Source DB:  PubMed          Journal:  Acta Pharm        ISSN: 1330-0075            Impact factor:   2.230


  2 in total

1.  A water-damaged home and health of occupants: a case study.

Authors:  Jack Dwayne Thrasher; Michael R Gray; Kaye H Kilburn; Donald P Dennis; Archie Yu
Journal:  J Environ Public Health       Date:  2011-12-15

2.  Verruculogen associated with Aspergillus fumigatus hyphae and conidia modifies the electrophysiological properties of human nasal epithelial cells.

Authors:  Khaled Khoufache; Olivier Puel; Nicolas Loiseau; Marcel Delaforge; Danièle Rivollet; André Coste; Catherine Cordonnier; Estelle Escudier; Françoise Botterel; Stéphane Bretagne
Journal:  BMC Microbiol       Date:  2007-01-23       Impact factor: 3.605

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.